Cancers, Vol. 10, Pages 236: A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC

Cancers, Vol. 10, Pages 236: A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC

Cancers doi: 10.3390/cancers10070236

Authors: Juliet A. Carmichael Daisy Wing-san Mak Mary O'Brien

Until recently, chemotherapy has remained the mainstay of treatment for the majority of patients with advanced non-small cell lung cancer (NSCLC). Excellent responses have been observed with immune-checkpoint inhibitors, and targeted treatments for those tumours with actionable mutations, resulting in a paradigm shift in the treatment approach for these patients. Elderly patients and those with poor performance status (PS), such as Eastern Cooperative Oncology Group (ECOG) 2, have historically been excluded from clinical trials due to poor outcomes. There is therefore a lack of data to define the optimal treatment strategy for these patients. Due to improved tolerability of novel therapies, inclusion of these patients in clinical trials has increased, and sub-group analyses have identified many treatments demonstrating potential activity. Here, we summarise key recent advances in the treatment of NSCLC, specifically evaluating their efficacy and tolerability in these patient cohorts.

https://ift.tt/2L5UdJO